If you or a loved one has been diagnosed with non-muscle-invasive bladder cancer (NMIBC), your doctor may recommend a treatment called bacillus Calmette-Guérin (BCG) immunotherapy. NMIBC is an early-stage form of bladder cancer in which cancer cells haven’t spread into the muscle wall.
BCG therapy is widely used for NMIBC and can help reduce the risk of the cancer coming back or progressing.
BCG therapy is a type of intravesical immunotherapy. Intravesical means that the cancer treatment is placed directly into the bladder. Immunotherapy means that it activates the body’s immune system to attack cancer cells.
BCG therapy involves a liquid drug that contains a weakened version of the bacteria used in the tuberculosis vaccine. This bacterium, called Mycobacterium bovis, is strong enough to kick-start the immune system without making most people sick. People with weakened immune systems may be at higher risk for a serious infection, so your healthcare team will carefully check you for any immune issues before recommending this type of treatment.
During therapy, the BCG solution comes in direct contact with the bladder’s inner lining. The immune-activating effects work well for early-stage cancer. It’s also an effective treatment for some cases of intermediate- and high-risk NMIBC.
There are several situations in which BCG treatment may need to be delayed or avoided, such as an active urinary tract infection (UTI), traumatic catheterization, recent transurethral resection of bladder tumor (TURBT) or biopsy, weakened immune system, or current antibiotic treatment.
BCG therapy is often recommended after TURBT. During this procedure, a surgeon removes any visible bladder tumors.
When combined with TURBT, BCG therapy is considered an effective treatment for NMIBC. BCG treatment is usually recommended for people with intermediate- or high-risk NMIBC. If your cancer is at a different stage, such as low-grade bladder cancer, other strategies may be considered as well.
A course of BCG therapy involves multiple visits. The schedule and length of treatment are based on a variety of factors, including your type of NMIBC, your response to treatment, and your healthcare team’s recommendations.
The first phase, called induction therapy, typically lasts six weeks. The treatment is given once a week. After that, you may move to maintenance therapy, which is given every few weeks or months.
Maintenance therapy usually lasts one year for people with intermediate-risk NMIBC and up to three years for those with high-risk NMIBC.
Before your first BCG treatment, your healthcare team will give you clear instructions.
Usually, they’ll ask you not to drink anything for a few hours before your appointment. This helps ensure your bladder is empty and ready for the treatment. Your provider will also make sure you don’t have a UTI.
At the start of the procedure, your provider will apply local anesthesia (numbing medicine) around the urethra (the opening where urine leaves the body) to reduce any discomfort. Next, they’ll gently insert a thin, flexible tube called a catheter through the urethra into your bladder.
The BCG liquid is then delivered through the catheter and into your bladder. After the liquid is in, the catheter is removed.
You’ll be asked to hold the liquid in your bladder for about two hours. It’s especially important not to pee for at least the first hour so the medicine can stay in contact with your bladder lining and activate your immune system. While it’s best to hold the liquid in the bladder for two hours, you can always inform your nurse or doctor if you cannot tolerate this duration.
For the first six hours after a BCG treatment, you’ll need to take special precautions with your urine because it can contain live BCG bacteria. You’ll need to protect others from coming into contact with the live bacteria in your urine. This is especially important if you’re around people with weakened immune systems, who may be more at risk of infection.
Follow these safety steps:
Many people experience mild side effects within 24 hours after BCG therapy. These side effects are usually temporary and can be managed with over-the-counter or prescription medications. Common side effects include:
Some of these may be similar to symptoms of bladder cancer.
Check with your care team before taking medications for side effects or other conditions, especially antibiotics. Antibiotics may interfere with BCG, and treatment may need to be postponed.
Very rarely, BCG bacteria can cause a serious infection that spreads beyond the bladder.
Call your healthcare provider immediately if you develop severe or persistent flu-like symptoms or any of the following symptoms:
Some people may not be able to tolerate BCG therapy because of side effects. Other treatment options include intravesical chemotherapy. Talk with your urologist or another member of your healthcare team if you’re having trouble with side effects from BCG therapy and want to discuss other options.
Research shows that about 60 percent of people whose NMIBC responds to BCG therapy will still be cancer-free for more than five years. To help lower the risk of cancer coming back, it’s important to follow the maintenance BCG schedule that your cancer care team recommends.
BCG therapy can also be used with another immunotherapy called durvalumab (Imfinzi), an immune checkpoint inhibitor. In May 2026, this combination was approved by the U.S. Food and Drug Administration (FDA) for people with high-risk NMIBC not previously treated with BCG.
However, BCG therapy doesn’t work for everyone. Some studies show that 30 percent to 50 percent of people with NMIBC who receive BCG have cancer that doesn’t respond adequately to treatment. It can mean that tumors don’t shrink, new tumors appear, or the cancer returns during or after treatment.
If your cancer doesn’t respond or comes back, your healthcare team will talk with you about other treatment options for BCG-refractory NMIBC (meaning non-muscle-invasive bladder cancer that hasn’t responded to BCG treatment).
In some cases, your urologist may recommend another course of BCG therapy after the first course doesn’t fully control the cancer. If the cancer is considered BCG-unresponsive, other treatments or surgery may be recommended instead.
A radical cystectomy (surgery to remove the bladder) has traditionally been the standard next course of treatment. However, some people aren’t good candidates for major surgery or don’t want to lose their bladder.
Fortunately, more treatment options are now available for NMIBC, including several FDA-approved treatments that don’t require major surgery.
Chemotherapy may also be an option. Mitomycin intravesical solution (Zusduri) was FDA-approved in 2025 for recurrent low-grade, intermediate-risk NMIBC.
For BCG-unresponsive NMIBC with carcinoma in situ (CIS), with or without papillary tumors, several FDA-approved bladder-preserving treatments are available, including:
These treatments have shown to be effective treatments for BCG-unresponsive bladder cancer, and research is ongoing. Many more combinations of drugs are being studied in clinical trials. Your care team will help you weigh the pros and cons of each option and choose what’s best for your situation.
Get updates directly to your inbox.
Should I see urologist or oncologist for high grade nmibc recently diagnosed
Become a member to get even more
This is a member-feature!
Sign up for free to view article comments.
Anyone have any suggestions I am all ears 😃
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.